Investors & Media

Alexis Borisy has served as a member of our Board of Directors since April 2011. Mr. Borisy co-founded Blueprint Medicines and served as Interim Chief Executive officer from May 2013 through July 2014. Mr. Borisy is Co-Founder and Operating Chairman of Curie.Bio, Inc., a venture capital firm focused on helping entrepreneurial founders launch therapeutics companies. He also co-founded IDRx, Inc., a biopharmaceutical company focused on precision combination oncology therapies. Previously, Mr. Borisy was a partner at Third Rock Ventures, a life sciences venture capital firm focused on the formation, development and strategy of new companies. Mr. Borisy currently serves as Chairman and member of the Audit, Compensation and Research and Development Committees of the Board of Directors of Relay Therapeutics, Inc. He also serves as Chairman and member of the Audit and Compensation Committees of the Board of Directors of Tango Therapeutics, Inc., and as a member of the Compensation and Nominating and Corporate Governance Committees of the Board of Directors of Revolution Medicines, Inc. Mr. Borisy previously served on the Board of Directors of Magenta Therapeutics, Inc., Editas Medicine, Inc. and FORMA Therapeutics, Inc. and as Chairman of the Board of Directors at EQRx, Inc. Mr. Borisy co-founded Foundation Medicine, Inc., serving as Interim Chief Executive Officer from 2009 to 2011 and as Chairman of the Board of Directors from 2011 to 2017 until its acquisition by Roche. In 2000, Mr. Borisy founded CombinatoRx, Inc. and served as its Chief Executive Officer and as a member of its Board of Directors. Mr. Borisy received a B.S. in chemistry from the University of Chicago and an M.S. in chemistry and chemical biology from Harvard University.